.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC23_Olokizumab.Olokizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC23_Olokizumab.Olokizumab| name: | Olokizumab |
| ATC code: | L04AC23 | route: | subcutaneous |
| n-compartments | 2 |
Olokizumab is a humanized monoclonal antibody targeting interleukin-6 (IL-6), used for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). It was approved in Russia in 2020 for rheumatoid arthritis and is under clinical development elsewhere.
Pharmacokinetic estimates for olokizumab in adult patients with rheumatoid arthritis based on typical monoclonal antibody PK behavior and limited published clinical data.